Phio Pharmaceuticals Corp./$PHIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Ticker
$PHIO
Sector
Primary listing
Employees
6
Headquarters
Website
PHIO Metrics
BasicAdvanced
$14M
-
-$1.45
0.91
-
Price and volume
Market cap
$14M
Beta
0.91
52-week high
$4.19
52-week low
$0.81
Average daily volume
7.4M
Financial strength
Current ratio
16.027
Quick ratio
15.695
Profitability
EBITDA (TTM)
-9.217
Management effectiveness
Return on assets (TTM)
-42.33%
Return on equity (TTM)
-69.95%
Valuation
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-0.884
Free cash flow yield (TTM)
-113.17%
Free cash flow per share (TTM)
-1.335
Growth
Earnings per share change (TTM)
-83.99%
3-year earnings per share growth (CAGR)
-74.81%
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
Newsfile Corp·4 days ago
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
Newsfile Corp·1 week ago
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
Newsfile Corp·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phio Pharmaceuticals Corp. stock?
Phio Pharmaceuticals Corp. (PHIO) has a market cap of $14M as of March 20, 2026.
What is the P/E ratio for Phio Pharmaceuticals Corp. stock?
The price to earnings (P/E) ratio for Phio Pharmaceuticals Corp. (PHIO) stock is 0 as of March 20, 2026.
Does Phio Pharmaceuticals Corp. stock pay dividends?
No, Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Phio Pharmaceuticals Corp. dividend payment date?
Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. (PHIO) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.